Drug Safety

Day 4 was a half day closeout to the EULAR 2023 Congress. For me the big presentations were the late breaking abstracts, although there were other review and abstract sessions for those remaining.…

Some subjects in rheumatology seem to create contention the more they get explored, and one of those areas is a traditional crowd favourite for discussion at EULAR - clinically suspect arthralgias.…

There is a clear unmet need for new and effective therapies in primary Sjogren’s Syndrome (pSS) patients, as there are no current licensed therapies.   Therapeutic development in pSS appears to…

Day 3 was a sunny warm day in Milan at the 2023 EULAR Congress meeting. Here are a few of my favorite abstracts from today. Rheumatoid Factor Lowering Predicts Improved Outcomes in RA. Abstract…

Rheumatoid arthritis (RA) is known to be historically associated with site specific cancers, especially lung skin and lymphomas. This risk was described as likely to be supported by chronic systemic…

Risk of poor pregnancy outcomes in lupus patients continues to remain high, especially in the setting of high disease activity. Significant racial and ethnic disparities are also described in this…

Day 2 at the international EULAR Congress meeting is always bigger and busier.  There are more sessions to choose from, more bodies fighting for space on the escalators and at the lunch lines,…

The pharmacology treatment in systemic lupus erythematosus (SLE) is a rapidly expanding field of research that provides excitement and optimism to both the patients and the clinicians. As we have…

In the last 2 years, there has been more caution and vigilance with the use of JAK inhibitors in the treatment of rheumatoid arthritis (RA) due to the risk of cardiovascular (CV) events. These CV…

Interstitial lung disease (ILD) is a severe extra articular manifestation of RA, with limited treatment strategies and poor prognosis. While for a long time RA treatments, such as methotrexate (MTX…